Merck Sharp + Dohme Corp.

Ambit Biosciences Corporation

Merck + Co., Inc.

Brian T Campbell

Ian M Bell

Shripad S Bhagwat

Martin W Rowbottom

Qi Chao

Mark W Holladay

Kelly G Sprankle

Eduardo Setti

Andiliy Gokching Lai

Sunny Abraham

Brendan M Crowley

Raffaella Faraoni

Brian Andrew Stearns

Andrew John Harvey

Benito Munoz

Thomas J Greshock

Jeannie M Arruda

Kenneth J Leavitt

Jean-Michel Andre Vernier

Songnian Lin

Bowei Wang

Joseph Leslie Duffy

Jiayi Xu

John M Sanders

Mark T Bilodeau

Jun Liang

Emma R Parmee

Feroze Ujjainwalla

Ping Liu

Mark E Layton

John S Debenham

Lida R Tehrani

Peter J Manley

Helen Y Chen

Subharekha Raghavan

Harry R Chobanian

Tony Siu

Anthony J Roecker

Richard Berger

Dharam Paul

Timothy A Blizzard

Libo Xu

Deodial Guy Guiadeen

Sunita V Dewnani

Nicholas D P Cosford

Essa H Hu

William D Shipe

Jacob M Hoffman

Guizhen Dong

Dann LeRoy Parker, Jr

Timothy Allen Blizzard

Celine Bonnefous

Zhiqiang Yang

Vanessa L Rada

Belinda C Huff

Rui Zhang

Christophe Morice

Yiwei Li

Zhiyong Hu

Zhiqiang Guo

Bart Harper

Joie Garfunkle

Kevin J Rodzinak

Alexander J Kim

Ming Wang

Olga Ornoski

Candido Gude

Jean-Marie Contreras

Zack Zhiqiang Guo

Byron Dubois

Xiumin Zhao

Roman Kats-Kagan

Rowena Villanueva Cube

Fabrice Garrido

Christophe Joseph

James I Fells

Patrick Bazzini

Linda M Suen

Naomi Burke Anker

James Fells

Aurelie Witzel

Zhiquang Yang

Janet Lorraine Gunzer

Tao Hu

Joseph L Duffy

Deodial G Guiadeen

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I). 

The present disclosure relates to compounds of formula (I) that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. 

Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. 

Isoquinoline derivatives as MGAT2 inhibitors

Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

RAF kinase modulator compounds and methods of use thereof

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation 

Allosteric modulators of nicotinic acetylcholine receptors

A compound of Formula II or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula II, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula II or a pharmaceutically acceptable salt thereof. 

Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators

Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. 

Glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O); Ris O or S. 

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

Inhibitors of Akt activity

6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other.

[object Object]

Growing community of inventors

Burlington, NJ, United States of America

Brian T Campbell